2218 ⎘
Animals characterised by purpose; Animal model, e.g. for test or diseases Animal model for proliferative diseases
HUMAN SEBACEOUS GLAND CARCINOMA CELL LINE AND US THEREOF
#2COMPOSITIONS AND METHODS FOR DELIVERY OF IMMUNE CELLS TO TREAT UN-RESECTABLE OR NON-RESECTED TUMOR CELLS AND TUMOR RELAPSE
#3GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD98HC
#4METHOD FOR PRODUCING A SPONTANEOUS METASTASIS MODEL
#5IMMUNODEFICIENT NON-HUMAN ANIMALS FOR ASSESSING DRUG METABOLISM AND TOXICITY
#6Genetically Modified Mice and Engraftment
#7METHODS AND MODELS FOR ASSESSING EFFICACY OF IMMUNOTHERAPIES
#8METHOD AND ANIMAL MODEL FOR INDUCING BCC TUMORS
#9GENETICALLY ENGINEERED MICE MODELS FOR MULTIPLE MYELOMA
#10SCREENING METHODS FOR TARGETS FOR CANCER THERAPY
#11ZEBRAFISH MODEL OF HUMAN ACUTE MYELOID LEUKEMIA AND METHOD OF USE THEREOF
#12ANIMAL MODELS AND METHODS OF USE
#13METHODS OF CULTURING TUMOR INFILTRATING LYMPHOCYTES
#14NON-HUMAN ANIMALS HAVING A HUMANIZED TSLP GENE, A HUMANIZED TSLP RECEPTOR GENE, AND/OR A HUMANIZED IL7RA GENE
#15BRAIN TUMOR MODEL
#16METHODS FOR IDENTIFYING AND USING ALLOGENEIC TUMOR INFILTRATING LYMPHOCYTES TO TREAT CANCER
#17BRAIN-METASTATIC LUNG CANCER CELL LINE AND USE OF NOGGIN AS MARKER FOR BRAIN METASTASIS OF LUNG CANCER
#18DELIVERY AND USE OF THE CRISPR-CAS SYSTEMS, VECTORS AND COMPOSITIONS FOR HEPATIC TARGETING AND THERAPY
#19METHOD AND DEVICE FOR DRUG SCREENING
#20Genetically Modified Non-Human Animals And Methods Of Use Thereof
#21ANIMAL MODELS OF RECCURRENT HEPATOCELLULAR CARCINOMA AND USES THEREOF
#22HUMANIZED MOUSE MODELS
#23ANIMAL MODEL OF CD19 CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY FOR LEUKEMIA COMPLICATED BY CYTOKINE RELEASE SYNDROME (CRS), AND PREPARATION METHOD AND USE THEREOF
#24NON-HUMAN ANIMALS HAVING A HUMANIZED LYMPHOCYTE-ACTIVATION GENE 3
#25GENETICALLY MODIFIED MOUSE THAT EXPRESSES HUMANIZED PD1 AND PD-L1 PROTEINS
#26TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON
#27NON-HUMAN ANIMALS HAVING A HUMANIZED PROGRAMMED CELL DEATH 1 GENE
#28UT2 GENE-DEFICIENT MOUSE MODEL AND METHOD FOR SCREENING THERAPEUTIC AGENT FOR MYELOID LEUKEMIA, USING SAME
#29INHIBITORS OF THE IRE-1/XBP-1 PATHWAY AND METHODS OF USING THEREOF
#30NME INHIBITORS AND METHODS OF USING NME INHIBITORS
#31GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC TFR1
#32HUMAN NSCLC CELL LINES AND USES THEREOF
#33GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL1RAP
#34COMPOSITIONS AND METHODS FOR TREATING INDIVIDUALS WHO HAVE ONCOGENE-NEGATIVE CANCER
#35GENETICALLY MODIFIED RAT MODELS FOR SEVERE COMBINED IMMUNODEFICIENCY (SCID)
#36NON-HUMAN ANIMALS HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENE
#37GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3 GENES
#38COMPOSITIONS AND METHODS FOR DELIVERY OF IMMUNE CELLS TO TREAT UN-RESECTABLE OR NON-RESECTED TUMOR CELLS AND TUMOR RELAPSE
#39Genetically modified non-human having humanized gamma and delta TCR variable genes
#40METHOD FOR CULTURING 3-DIMENSIONAL LUNG CANCER ORGANOID AND METHOD FOR PREPARING PATIENT-DERIVED XENOGRAFT ANIMAL MODEL USING SAME
#41SIMULATION METHOD FOR CHRONIC ATROPHIC GASTRITIS (CAG) LESION AND IDENTIFICATION METHOD FOR MOUSE MODELING
#42Materials for Tumor Inoculation in Murine Mouse Models and Uses Thereof
#43METHOD OF DETERMINING RESISTANCE TO CHECKPOINT INHIBITOR THERAPIES
#44GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CCR8
#45GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF
#46COMPOSITION AND METHOD FOR MODULATING FIBROBLAST GROWTH FACTOR RECEPTOR 3 ACTIVATION
#47ANIMAL MODEL OF BRAIN TUMOR AND MANUFACTURING METHOD OF ANIMAL MODEL
#48ENGINEERED CELLS, ANIMAL MODELS, AND USES THEREOF FOR MODELING LOW GRADE GLIOMA (LGG)
#49NON-HUMAN ANIMALS HAVING A HUMANIZED CXCL13 GENE
#50GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD276
#51ANIMAL MODEL FOR STUDYING CANCER IMMUNOTHERAPY
#52METHOD FOR SEARCHING AND SCREENING FOR TARGET OF ANTI-CANCER AGENT USING NON-HUMAN ANIMAL MODEL HAVING NOG ESTABLISHED CANCER CELL LINE TRANSPLANTED THEREIN
#53SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
#54BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOF
#55TARGETING GLIOBLASTOMA STEM CELLS THROUGH THE TLX-TET3 AXIS
#56ANTI-MUC16 ANTIBODIES AND USES THEREOF
#57METHOD FOR SCREENING ANTICANCER AGENT AND COMBINATION DRUG OF KINASE INHIBITORS FOR TREATMENT OF PANCREATIC CANCER
#58LMP-1 EXPRESSING CELLS AND METHODS OF USE THEREOF
#59METHODS OF PRODUCING GRANULOMAS AND ANIMAL MODELS OF SARCOIDOSIS
#60SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (dRMCE) AND DISEASE MODELS THEREOF
#61GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC IL33
#62GENETIC MODIFICATION NON-HUMAN ORGANISM, EGG CELLS, FERTILIZED EGGS, AND METHOD FOR MODIFYING TARGET GENES
#63ZEBRAFISH DELETION AND COMPOUND MUTANTS AND USES THEREOF
#64MOUSE MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
#65NME INHIBITORS AND METHODS OF USING NME INHIBITORS
#66GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD73
#67METHOD FOR ENHANCING TUMOR GROWTH
#68NON-HUMAN ANIMALS HAVING A HUMANIZED TSLP GENE, A HUMANIZED TSLP RECEPTOR GENE, AND/OR A HUMANIZED IL7RA GENE
#69MODELING ONCOLOGY ON DEMAND
#70Genetically modified rat models for severe combined immunodeficiency (SCID)
#71Method for integrating biological tissues with a vascular system
#72NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#73NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT
#74Mouse model of alcohol-induced liver cancer
#75METHOD AND DEVICE FOR DRUG SCREENING
#76TRANSGENIC MODELS FOR STEM CELL THERAPIES
#77SMALL MOLECULE DEGRADERS OF FKBP12 VIA RECRUITMENT OF VON HIPPEL-LINDAU E3 UBIQUITIN LIGASE (VHL) E3 UBIQUITIN LIGASE, AND USES IN dTAG SYSTEMS
#78NON-HUMAN ANIMAL MODELS OF SÉZARY SYNDROME
#79GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD137
#80Phosphorylated dicer antibody and methods of use thereof
#81A METHOD FOR SCREENING A THERAPEUTIC AGENT FOR CANCER USING BINDING INHIBITOR OF CYCLIN-DEPENDENT KINASE 1 (CDK1)-CYCLIN B1 AND RETINOIC ACID RECEPTOR RESPONDER 1 (RARRES1) GENE KNOCKOUT ANIMAL MODEL
#82EZH2- FGFR INHIBITION IN CANCER
#83ANIMAL MODEL FOR AMPLIFYING HUMAN OR ANIMAL CIRCULATING TUMOR CELLS
#84Genetically Modified Mice and Engraftment
#85COMPOSITIONS AND METHODS UTILIZING GENETICALLY-MODIFIED ANIMALS AND CELLS
#86GENETICALLY MODIFIED ANIMAL WITH CANINE OR CHIMERIC PD-1
#87METHOD FOR CONSTRUCTING LUNG CANCER ANIMAL MODEL
#88ISOLATED NASOPHARYNGEAL CARCINOMA CELLS AND DERIVATIVES PREPARED THEREOF
#89Genetically modified rat models for severe combined immunodeficiency (SCID)
#90Genetically modified non-human animals and methods of use thereof
#91Non-human animals having a humanized lymphocyte-activation gene 3
#92INTERLEUKIN-8 FOR MAINTENANCE OF HUMAN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME AND USES THEREOF
#93USE OF AN EGG GRAFTED WITH TUMOR CELLS IN ORDER TO STUDY THE ANTI-CANCER EFFECTIVENESS OF IMMUNE THERAPIES IN THE ABSENCE OF IMMUNE EFFECTOR CELLS OTHER THAN THOSE IN THE GRAFTED EGG
#94COMPOSITIONS AND METHODS FOR TREATING A TUMOR SUPPRESSOR DEFICIENT CANCER
#95Mutant Mouse-Derived Pancreatic Organoid and Method for Evaluating Standardized Drug for Efficacy
#96COMPOSITIONS AND METHODS FOR TREATING A TUMOR SUPPRESSOR DEFICIENT CANCER
#97METHODS FOR TREATING PTEN DEFICIENT EPITHELIAL CANCERS USING A COMBINATION OF ANTI-PI3KBETA AND ANTI-IMMUNE CHECKPOINT AGENTS
#98Genetically modified non-human animal with human or chimeric CD3e
#99Non-human animals having a humanized signal-regulatory protein gene
#100Isolation of novel AAV's and uses thereof
#101ANIMAL MODEL FOR HEPATOCELLULAR CARCINOMA AND USES THEREOF
#102Mouse having a humanized cluster of differentiation 47 gene
#103SINGLE BRAIN CELL-DERIVED ORGANOIDS
#104Transgenic mouse model of Neurofibromatosis type 1
#105Humanized Mouse Model
#106SINGLE LUNG CELL-DERIVED ORGANOIDS
#107Single kidney cell-derived organoids
#108Method for culturing 3-dimensional lung cancer organoid and method for preparing patient-derived xenograft animal model using same
#109Genetically modified mouse that expresses humanized PD1 and PD-L1 proteins
#110IMMUNODEFICIENT NON-HUMAN ANIMAL
#111NOVEL IMMUNODEFICIENT RAT FOR MODELING HUMAN CANCER
#112PRODUCTION AND USE OF RED BLOOD CELLS
#113Genetically modified non-human animal with human or chimeric IL15
#114Method for preparing a large animal model with peritoneal carcinomatosis
#115Genetically modified non-human animal with human or chimeric LAG3
#116Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
#117Molecular imaging method for evaluating liver regeneration capacity after ALPPS operation
#118PD-1 peptide inhibitors
#119Delivery and use of the CRISPR-CAS systems, vectors and compositions for hepatic targeting and therapy
#120Non-Mammalian RAS Transgenic Animal Model
#121CANCER IMAGING WITH THERAPY: THERANOSTICS
#122A GANGLIOGLIOMA-INDUCED ANIMAL MODEL AND A METHOD FOR DIAGNOSING AND TREATING GANGLIOGLIOMA AND RELATED DISEASES
#123Rapid tumorigenicity screening system
#124TARGETING GLIOBLASTOMA STEM CELLS THROUGH THE TLX-TET3 AXIS
#125Modulating biomarkers to increase tumor immunity and improve the efficacy of cancer immunotherapy
#126METHODS AND COMPOSITIONS FOR ALLEVIATING CYTOKINE RELEASE SYNDROME
#127METHODS OF MOUSE CLINICAL TRIAL
#128P21-Activated Kinase Inhibitor Domain Targeted Transgenic Mouse
#129IMMUNODEFICIENT MICE EXPRESSING HUMAN INTERLEUKIN 15
#130SIGNATURES AND DETERMINANTS ASSOCIATED WITH PROSTATE CANCER PROGRESSION AND METHODS OF USE THEREOF
#131Genetically modified non-human animals and methods of use thereof
#132DIET CONTROLLED EXPRESSION OF A NUCLEIC ACID ENCODING A PRO-APOPTOTIC PROTEIN
#133Non-human animals having a humanized signal-regulatory protein gene
#134Methods for cancer treatment
#135METHODS OF USING VARIANTS OF FGF19 POLYPEPTIDES FOR THE TREATMENT OF CANCER
#136Bispecific recombinant protein and use thereof
#137PERSONALIZED ANTI-CANCER AGENT SCREENING SYSTEM
#138Anti-tumor properties of Dickkopf 3b
#139Mesothelin vaccines and model systems
#140Genetically modified non-human animals and methods of use thereof
#141Non-human animals having a humanized programmed cell death 1 gene
#142METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
#143METHODS OF A DROSOPHILA MODEL FOR CHRONIC MYELOID LEUKEMIA (CML) TREATMENT
#144Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof
#145Genetically modified non-human animal with human or chimeric PD-L1
#146Cell and utilization thereof
#147Anti-NRP1 antibody screening method
#148Systems and methods for in vivo dual recombinase-mediated cassette exchange (dRMCE) and disease models thereof
#149Genetically modified mice expressing humanized PD-1
#150MUTANT MOUSE-DERIVED PANCREATIC ORGANOID AND USE THEREOF
#151Genetically modified non-human animal with human or chimeric CD3e
#152Genetically modified non-human animal with human or chimeric PD-1
#153Genetically modified non-human animal with human or chimeric CTLA-4
#154Method of using a genetically modified mouse that expresses a humanized CTLA-4 gene
#155Animal model of longevity and related methods for increasing longevity and inhibiting tumorigenesis
#156Method and System of Harvesting Extracellular Vesicles Using Hydrogel Particles for Later Delivery to, and Remodeling of, an Immune System
#157Genetically modified non-human animal with human or chimeric GITR
#158Genetically modified non-human animal with human or chimeric LAG-3
#159Composition and method for modulating fibroblast growth factor receptor 3 activation
#160Genetically modified non-human animal with human or chimeric TIM-3
#161TUMOR CELL XENOGRAFT MODEL IN ZEBRAFISH, AND METHODS OF CONSTRUCTING AND USING THE SAME
#162Genetically modified mouse comprising a chimeric TIGIT
#163HYBRID NUCLEIC ACID MOLECULES AND THEIR USE
#164Genetically modified non-human animal with human or chimeric CD27
#165Genetically modified non-human animal with human or chimeric CD137
#166Method for constructing PD-1 gene modified humanized animal model and use thereof
#167HUMANIZED IL-7 RODENTS
#168Genetically modified non-human animal with human or chimeric CD28
#169Genetically modified non-human animal with human or chimeric TIGIT
#170HUMANIZED MOUSE MODEL WITH IMPROVED HUMAN INNATE IMMUNE CELL DEVELOPMENT
#171Non-human animals having a humanized lymphocyte-activation gene 3
#172Immunodeficient non-human animal
#173Three Dimensional Bioprinted Tumor Models for Drug Testing
#174Methods for treating PTEN deficient epithelial cancers using a combination of anti-PI3KBETA and anti-immune checkpoint agents
#175Genetically modified mice and engraftment
#176Isolation of novel AAV's and uses thereof
#177Methods of treating cells containing fusion genes by genomic targeting
#178Genetically modified non-human animal with human or chimeric PD-L1
#179Cancer Treatment and Immune System Regulation Through FAT10 Pathway Inhibition
#180ANIMAL MODELS OF CANCER
#181AAV delivery of shRNA for treatment of pancreatic cancer
#182Methods and materials for using butyrylcholinesterases to treat cancer
#183Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
#184Animal model of brain tumor and manufacturing method of animal model
#185Biomarkers and label-free nucleic acid biomarker detection in cancer and other diseases
#186Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators
#187LMP1-expressing cells and methods of use thereof
#188METHOD AND DEVICE FOR DRUG SCREENING
#189Non-human animals having a humanized signal-regulatory protein gene
#190High-affinity anti-human folate receptor beta antibodies and methods of use
#191Oncogenic Models Based on Delivery and Use of the CRISPR-Cas Systems, Vectors and Compositions
#192Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
#193THERAPEUTIC TARGETS FOR LIN-28-EXPRESSING CANCERS
#194METHODS OF IDENTIFYING AND TREATING IMMUNE CHECKPOINT INHIBITOR-RESPONSIVE NEOPLASMS AND CELLS, TRANSGENIC ANIMALS AND KITS FOR USE THEREIN
#195Compounds for inducing proliferation and differentiation of cells, and methods of use thereof
#196HUMANIZED MOUSE MODEL FOR CANCER METASTASIS
#197Genetically modified non-human animals and methods of use thereof
#198GENETIC MODIFICATION NON-HUMAN ORGANISM, EGG CELLS, FERTILIZED EGGS, AND METHOD FOR MODIFYING TARGET GENES
#199REGULARLY ARRANGED SPHEROIDS HAVING EQUAL SIZES AND USE THEREOF
#200Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
#201Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
#202Transgenic mouse expressing human cereblon
#203Targeting glioblastoma stem cells through the TLX-TET3 axis
#204Use of inhibitors of ADAM12 as adjuvants in tumor therapies
#205EFFICIENT, SCALABLE PATIENT-DERIVED XENOGRAFT SYSTEM BASED ON A CHICK CHORIOALLANTOIC MEMBRANE (CAM) IN VIVO MODEL
#206Human ARCAP transgenic mouse
#207FLY AVATARS FOR CANCER AND USES THEREOF
#208Animal study model for cancer
#209Humanized IL-7 rodents
#210MYC-REPORTERS, CELLS CONTAINING MYC-REPORTERS AND METHODS OF USE THEREOF
#211Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
#212SYSTEMS FOR DETECTING, MONITORING OR TREATING DISEASES OR CONDITIONS USING ENGINEERED CELLS AND METHODS FOR MAKING AND USING THEM
#213Genetically modified non-human animals and methods of use thereof
#214Genetically modified rat models for severe combined immunodeficiency (SCID)
#215Method for measuring tumor burden in patient derived xenograft (PDX) mice
#216Anti-cancer and anti-inflammatory therapeutics and methods thereof
#217COMPOSITIONS AND METHODS FOR CREATING PANCREATIC CANCER ANIMAL MODEL
#218Mouse lymphoma cell line and animal model of human high grade B-cell lymphoma
#219Delivery, use and therapeutic applications of the CRISPR-cas systems and compositions for modeling mutations in leukocytes
#220Method of using mouse having a humanized cluster of differentiation 47 gene
#221Immunity enhancing agent for cancer by Allergin-1 antagonist
#222PERSONALIZED TREATMENT OF DISEASES AND DISORDERS
#223PROCESS FOR INDUCING RESISTANCE TO DIPHTHERIA TOXIN IN HUMAN CELLS, PRODUCTS AND USES THEREOF
#224NON-HUMAN ANIMALS HAVING A HUMANIZED PROGRAMMED CELL DEATH 1 GENE
#225PD-1 peptide inhibitors
#226Non-human animal having human CD3 gene substituted for endogenous CD3 gene
#227Non-HLA matched humanized NSG mouse model with patient-derived xenograft
#228Production and use of red blood cells
#229Use of liposomes in a carrier comprising a continuous hydrophobic phase as a vehicle for cancer treatment
#230CELL STRUCTURE, NON-HUMAN MODEL ANIMAL, METHOD FOR PRODUCING NON-HUMAN MODEL ANIMAL, AND METHOD FOR EVALUATING TEST SUBSTANCE
#231Genetically modified mouse whose genome comprises a humanized CD274 gene
#232Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha
#233SCREENING METHODS FOR TARGETS FOR CANCER THERAPY
#234HUMANIZED MICE AND USES THEREOF
#235MMTV-SV40-Spy1A and Spy1A-pTRE transgenic mouse models
#236Non-human animals having a humanized signal-regulatory protein gene
#237Anti-MUC16 antibodies and uses thereof
#238Combination immune therapy and cytokine control therapy for cancer treatment
#239METHODS AND COMPOSITIONS RELATING TO AN EMBRYONIC STEM CELL-BASED TUMOR MODEL
#240Progressively tumorigenic cell lines
#241Mice with transgene of iBox peptide inhibitor of group B p21-activated kinases
#242Identification of a 5-Gene Expression Signature Predicting Clinical Outcome of Patients with Brain Tumors
#243Genetically Modified Non-Human Animals And Methods Of Use Thereof
#244SOLUBLE MIC NEUTRALIZING MONOCLONAL ANTIBODY FOR TREATING CANCER
#245Delivery, use and therapeutic applications of the CRISPR-Cas systems and compositions for modeling competition of multiple cancer mutations in vivo
#246CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
#247NRAS related cancer therapy
#248In vivo methods for identifying cancer-associated immunotherapy targets
#249P21-activated kinase inhibitor domain targeted transgenic mouse
#250Humanized IL-7 rodents
#251PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION AND TREATMENT, CONTAINING NDRG3 EXPRESSION OR ACTIVITY INHIBITOR AS ACTIVE INGREDIENT, OR NDRG3 PROTEIN-SPECIFIC ANTIBODY AND USE THEREOF
#252SIGNATURES AND PCDETERMINANTS ASSOCIATED WITH PROSTATE CANCER AND METHODS OF USE THEREOF
#253Animal model of longevity and related methods for increasing longevity and inhibiting tumorigenesis
#254Cancer treatment and immune system regulation through FAT10 pathway inhibition
#255Methods for establishing animal model of hepatocellular carcinoma bone metastasis
#256Non-human animals having a humanized signal-regulatory protein gene
#257METHOD FOR PRODUCING ANIMAL MODEL OF OSTEOBLASTIC BONE METASTASIS
#258Animal models, cell lines and methods for screening hepatitis C virus vaccines
#259Single cell-derived organoids
#260Engineered cell comprising a recombinant pro-methylation cis-element construct that resides in a regulatory region of a target gene
#261Genetically modified mice and engraftment
#262Isolation of novel AAV's and uses thereof
#263Isolation of novel AAV's and uses thereof
#264ANIMAL MODEL FOR STUDYING NEUROBLASTOMAS
#265Non-human animals having a humanized lymphocyte-activation gene 3
#266HUMANIZED MOUSE MODELS AND USES THEREOF
#267METHODS INVOLVING MACROPHAGE TUMOR CELL FUSION HYBRIDS
#268Transgenic mice expressing Y114F mutant prohibitin
#269Mesothelin vaccines and model systems
#270Humanized IL-7 rodents
#271Rodent model of prostate cancer
#272Methods of treating cancer using PD-1 axis binding antagonists and tigit inhibitors
#273Transgenic mouse for determining the role of senescent cells in cancer
#274Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
#275Natural-killer/T-cell lymphoma (NKTCL) susceptibility prediction, diagnosis and therapy
#276Method for manufacturing transgenic caenorhabditis elegans with DNA methyltransferase and use thereof
#277Non-human animals having a humanized signal-regulatory protein gene
#278Soluble MIC neutralizing monoclonal antibody for treating cancer
#279SIGNATURES AND DETERMINANTS ASSOCIATED WITH PROSTATE CANCER PROGRESSION AND METHODS OF USE THEREOF
#280Animal model of nash-induced hepatocellular carcinoma and methods for developing specific therapeutics
#281NON-HUMAN ANIMALS HAVING A HUMANIZED CLUSTER OF DIFFERENTIATION 47 GENE
#282Non-human animals having a disruption in a C9ORF72 locus
#283Anti-tumor properties of Dickkopf 3b
#284Recurrent gene fusions in prostate cancer
#285Genetically modified non-human animals and methods of use thereof
#286Production of fertile XY female animals from XY ES cells
#287MMTV-SV40-Spy1A and Spy1A-pTRE transgenic mouse models
#288Methods of using variants of FGF19 polypeptides for the treatment of cancer
#289Non-mammalian RAS transgenic animal model
#290Immune competent models of human disease
#291Method For Creating Endometriotic Cells And Endometriosis Model Animal
#292Immune-compromised zebrafish
#293MODEL OF COLORECTAL CANCER
#294Non-human animals having a humanized cluster of differentiation 47 gene
#295Genetically modified mouse whose genome comprises a humanized CD274 gene
#296Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
#297Isolation of novel AAV's and uses thereof
#298Screen and use of therapeutics for pancreatic ductal adenocarcinoma
#299Use of a truncated CCN1 promoter for cancer diagnostics, therapeutics and theranostics
#300Inhibitors of the IRE-1/XBP-1 pathway and methods of using thereof